Karyopharm appoints Kristin Abate as VP, Chief Accounting Officer, effective Nov 20, 2024

Karyopharm Therapeutics Inc.

Kristin Abate appointed Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.
She continues as interim principal financial officer; designated as principal accounting officer.
Abate has been with Karyopharm since July 2019, most recently as VP Accounting, Corporate Controller, Assistant Treasurer.
Prior to Karyopharm, she spent 12 years at PricewaterhouseCoopers LLP; CPA with MS in Accountancy from Boston College.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kristin Abate

Vice President, Chief Accounting Officer

KPTI · Karyopharm Therapeutics Inc.

Effective: 2024-11-20
Filed: November 20, 2024, 6:59 PM ET

On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristin Abate was appointed as Vice President, Chief Accounting Officer at Karyopharm Therapeutics Inc..

Action: appointed
Role: Vice President, Chief Accounting Officer

Exact text from the filing

On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-262541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.